Previous 10 | Next 10 |
Wave Life Sciences (NASDAQ:WVE) priced an underwritten offering of 25.5M shares at an offering price of $2.15/share and to RA Capital Management, in lieu of ordinary shares, pre-funded warrants to purchase up to 7.09M shares. The per share offering price for the ordinary shares represent...
CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the ...
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Execu...
Then shares of Wave Life Sciences (NASDAQ:WVE) are trading lower in the morning hours Friday after H.C. Wainwright trimmed the price target for the clinical-stage genetic medicine company citing a lack of clarity on its clinical front in the near term. As the company plans to share results fo...
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Wave Life Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation
Wave Life Sciences Ltd. (WVE) Q1 2022 Earnings Conference Call May 12, 2022, 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development Kyle Moran ...
Wave Life Sciences press release (NASDAQ:WVE): Q1 GAAP EPS of -$0.62 misses by $0.06. Revenue of $1.75M (+17400.0% Y/Y) misses by $2.11M. As of March 31, 2022, Wave had $111.7 million in cash, cash equivalents and short-term investments. As of December 31, 2021, Wave had $...
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022 ...
Wave Life Sciences (NASDAQ:WVE) Q1 consensus EPS estimate is -$0.55 and consensus revenue estimate is $3.86M. WVE is scheduled to announce Q1 earnings results on Thursday, May 12, before market open. Over the last 3 months, EPS estimates have seen 4 upward revisions and 0 downw...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...